Back to results
US 12,180,517 B2Granted
Expression of novel cell tags
AssigneePrecigen, Inc.
InventorsRutul Shah, Peter Emtage, Ramya Yarlagadda
Life of this patent
Estimating the term…
Abstract
Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
Claims32
A method of treating cancer in a subject in need thereof the method comprising administering to the subject:
- (a) an engineered effector cell expressing a chimeric antigen receptor (CAR) that specifically binds to an antigen selected from CD19, CD20, CD33, BCMA, CD123, EGFRvIII, ROR1, HER2, GD2, mesothelin, CD22, and MUC-16;
- and (b) a binding partner selected from cetuximab, panitumumab, and functional fragments thereof;
- wherein:
- the engineered effector cell comprises a recombinant polypeptide comprising:
- (a) a truncated non-immunogenic HER1 polypeptide consisting of:
- (i) an amino acid sequence having at least 90% identity with SEQ ID NO:
- 200;
- and (ii) an amino acid sequence having at least 90% identity with any one of SEQ ID NOs:
- 203-209;
- and
- (b) a transmembrane domain comprising an amino acid sequence having at least 90% identity with any one of SEQ ID NOs:
- 26, 28, 30, 32, 34, 36, 38, and 40;
- and
- the cancer is associated with the overexpression of the antigen.
11 more elements
Dependencies are inferred from the claim text.